Guide · Pharmaceutical
The Pharmaceutical Artwork Approval Process
In pharma, artwork approval has to show that every label, leaflet and carton matches approved regulatory text. This guide covers the usual stages, reviewers, evidence and handover to contract manufacturers. It is not regulatory advice.
- Components
- Labels, PILs, cartons, foils
- Trigger
- Variation, safety update, new market, site change
- Key control
- Match to approved source text
- Cost to buyers
- Free guide, no obligation
How does pharmaceutical artwork approval differ?
Pharmaceutical artwork must reflect the product information approved by the regulator for each market. Approval is therefore not just a design decision: it requires proof that the text, layout and mandatory elements match the approved source, and that the process followed your quality procedures.
Changes are frequent: variations, safety updates, new pack sizes, market expansions and manufacturing site transfers each create artwork changes that must reach every affected component.
Typical stages of pharmaceutical artwork approval
- 1. Change request linked to an approved regulatory or quality change.
- 2. Impact assessment: which products, markets and components are affected.
- 3. Artwork creation from approved source text and controlled templates.
- 4. Proofreading and automated comparison against the source text.
- 5. Regulatory, technical and packaging reviews.
- 6. Quality approval of the final version.
- 7. Release to the printer or contract manufacturer, with the approved version recorded.
Working with contract manufacturers
When several CMOs or packaging sites are involved, each must receive the correct approved version and site-specific technical details. Emailing files outside the controlled workflow is a common source of error. Ask how any system or service gives CMOs controlled access and records which version each site received.
Who this guide is for
- Regulatory affairs and labelling teams.
- Packaging and artwork coordinators in pharma and biotech.
- Quality teams reviewing artwork procedures.
Common failure points
- Artwork built from outdated text.
- One affected component missed during a change.
- Country variants drifting from the master.
- Incomplete records of who approved the released version.
Strengthening the process
- 01
Link changes to source
Start every artwork change from an approved, versioned source.
- 02
Assess impact fully
List every affected component before work starts.
- 03
Proof against source
Compare text and graphics against approved content, not the previous artwork alone.
- 04
Control release
Record which approved version went to each printer or CMO.
Capabilities buyers usually look for
- Source text control
- Traceable link from approved text to artwork
- Audit trail
- Approval records suitable for inspection
- Electronic signatures
- Where your quality system requires them
- CMO access
- Controlled external review and handover
Choosing support
- Software if you have internal artwork and regulatory capacity.
- Regulatory artwork services if capacity is the constraint.
- Hybrid if you need both control and flexible capacity.
Questions to ask providers
- How is approved source text linked to artwork?
- What validation documentation do you provide, and what must we do ourselves?
- How do CMOs access and receive approved files?
- Can you show the full audit trail for a sample job?
Typical scenarios
Safety update
A text change must reach every pack in every affected market.
Site transfer
Manufacturer details change across many components.
Market expansion
New languages and local requirements are added.
Before changing your process
Involve quality early, update SOPs alongside any new tool, and pilot on a product family before extending. Verify provider claims about validation yourself.
Frequently asked questions
Who gives final approval for pharmaceutical artwork?
It depends on your quality system, but final release normally involves regulatory and quality sign-off after technical and packaging review. Your SOPs should define it.
Does using approval software make artwork compliant?
No. Software can support control and evidence, but compliance depends on your processes, content and quality oversight.
Official guidance (external)
- Directive 2001/83/EC (EUR-Lex) : EU legal framework for medicinal products, including labelling and package leaflets.
Requirements assessment
Get matched for pharmaceutical artwork
Tell us your components, markets and CMOs. A person reviews it before we suggest any provider.